Expression of Immune Molecules CD25 and CXCL13 Correlated with Clinical Severity of Myasthenia Gravis
Expression of Immune Molecules CD25 and CXCL13 Correlated with Clinical Severity of Myasthenia Gravis
复制标题
免疫分子CD25和CXCL13的表达与重症肌无力临床严重程度的相关性
DOI：
10.1007/s12031-013-9976-9
复制
发表时间：
2013-06-01
影响因子：
3.1
通讯作者：
Zhang, Wei
中科院分区：
文献类型：
--
作者：
Zhang, Min;Guo, Jun;Zhang, Wei
胸腺中免疫分子的差异表达已在病理结果中显示出来，包括重症肌无力（MG）。 CD25 是 T 细胞上表达的激活标记。 CXCL13 介导次级淋巴组织中 B 细胞的归巢和运动。在此，我们研究了 MG 或非 MG 胸腺增生患者胸腺中 CD25 和 CXCL13 的表达。共有 34 例伴有 MG 的胸腺增生患者（20 例全身性 MG (GMG) 和 14 例眼部 MG (OMG)）和 6 例无 MG 的胸腺增生患者入组，并使用免疫组织化学染色和实时聚合酶链反应对 CD25 和 CXCL13 进行分析。我们的研究表明，与患有 MG 的胸腺增生患者相比，伴 OMG 或 GMG 的胸腺增生中 CD25 和 CXCL13 的表达较高。根据免疫组化结果，我们观察到萎缩性胸腺和非 MG 增生性胸腺中的 CD25 表达显着低于婴儿胸腺（分别为 P= 0.002 和 0.005），与 CD25 表达相反，我们在三个对照组之间没有观察到 CXCL13 的差异表达。结果发现，OMG 或 GMG 的增生性胸腺的 CD25 表达水平显着高于非 MG 的患者（分别为 P= 0.007 和 0.001），并且与 OMG 的增生性胸腺相比，在增生性胸腺中观察到 CXCL13 的表达显着升高（P= 0.030）。实时PCR结果显示，非MG、OMG和GMG患者胸腺中CD25 mRNA表达趋势相似，但差异未达到显着性（P> 0.05）。与非 MG 和 OMG 患者相比，在增生性胸腺中发现了 CXCL13（分别为 P=≥0.003 和 0.071）。回归分析显示，胸腺 CD25 水平与 MG 症状严重程度呈正相关。 (F= 28.240;P= 0.000,r= 0.523)同样，胸腺CXCL13表达与MG疾病严重程度呈正相关(F= 36.093;P= 0.000,r= 0.671)。综上所述，我们的研究结果表明CD25和CXCL13参与了MG疾病的发病机制。 MG 并可能影响 MG 的临床症状。
Differential expressions of immune molecules have been shown in the thymi with pathological results, including myasthenia gravis (MG). CD25 is an activation marker expressed on T cells. CXCL13 mediates the homing and motility of B cells in secondary lymphoid tissues. Herein, we investigated the expressions of CD25 and CXCL13 in the thymi of thymic hyperplasia patients with MG or with non-MG. A total of 34 thymic hyperplasia patients with MG (20 generalized MG (GMG) and 14 ocular MG (OMG) and six thymic hyperplasia patients without MG were enrolled and analyzed using immunohistochemical staining and real-time polymerase chain reaction for CD25 and CXCL13. Our study demonstrated a higher expression of both CD25 and CXCL13 in hyperplastic thymi with OMG or GMG compared to those with non-MG. According to the immunohistochemical results, we observed that CD25 expression was significantly lower in atrophic thymi and non-MG hyperplastic thymi, compared with that in infant thymi (P= 0.002 and 0.005, respectively). In contrast to CD25 expression, we did not observe differential expression of CXCL13 among three control groups. And a similar CD25 mRNA expression was found in real-time polymerase chain reaction (PCR) results. We observed that both hyperplastic thymi with OMG or GMG expressed significantly higher levels of CD25 than those with non-MG (P= 0.007 and 0.001, respectively). And an increase of CD25 expression was observed in hyperplastic thymi with GMG compared to those with OMG (P= 0.030). Similarly, CXCL13 expression was significantly higher in hyperplastic thymi with GMG or with OMG than those with non-MG (P= 0.001 and 0.050, respectively). No significant CXCL13 expression difference was found between hyperplastic thymi with GMG and those with OMG (P>0.05). The real-time PCR results showed a similar tendency of CD25 mRNA expression among the thymi of non-MG, OMG, and GMG patients, but the difference did not reach significance (P> 0.05). An obvious increased expression of CXCL13 was found in hyperplastic thymi with GMG patients, compared to those with non-MG and OMG patients (P= 0.003 and 0.071, respectively). There was no difference found between hyperplastic thymi with non-MG and with OMG. Regression analysis showed a positive correlation between thymic CD25 level and MG symptom severity (F= 28.240;P= 0.000,r= 0.523). Similarly, a positive correlation was found between thymic CXCL13 expression and MG disease severity (F= 36.093;P= 0.000,r= 0.671). Taken together, our findings suggest CD25 and CXCL13 participate in the pathogenesis of MG and may influence the clinical symptoms of MG.